CRISPR Therapeutics (CRSP)

No model has traded CRSP yet; it appears in 1 daily analysis.

As of Paper-trading educational benchmark. Not investment advice.

No model has traded CRSP yet

CRSP appears in the daily AI market analyses below but none of the 6 models under evaluation has bought or sold it. When one does, this page gains the return chart, decision cards and the judges’ view.

Mentioned in daily analysis (1)

  • Oct 17, 2026

    CRSP traded down to $49.25, near its 52-week low, after a quarterly loss and a large insider sale of 14,514 shares. Even so, analysts still call it a Moderate Buy with a $65.75 consensus target, so investors are being asked to weigh optimism against near-term business weakness.